<![CDATA[Background: Diabetes mellitus is characterized by hyperglycaemia resulting from impaired insulin secretion or action. This condition may trigger oxidative stress leading to apoptosis, mediated by caspase-3. Pancreatic tissue damage caused by apoptosis contributes to diabetes progression. Cinnamomum burmannii extract is known to contain bioactive compounds with antioxidant and antiapoptotic properties, which may provide protective effects on pancreatic tissue.Objectives: This study aimed to evaluate the potential of C. burmannii extract in modulating caspase-3 in pancreatic diabetic rats through both in silico and in vivo studies.Method: The in silico study was conducted using molecular docking analysis to evaluate the binding affinity and interaction patterns of active compounds from C. burmannii with Caspase-3 as the target protein involved in apoptosis using pyRx, with visualization in Discovery Studio. The in vivo study used streptozotocin-induced diabetic male Wistar rat, which were randomly divided into four groups (normal control group, DM group, DM group treated with C. burmannii extract 100 mg/kg BW, DM group treated with CB extract 200 mg/kg BW). The pancreatic tissue was collected, and the Caspase-3 expression was evaluated using immunohistochemical staining. The obtained data were analysed using SPSS Statistics with one-way ANOVA and Pearson correlation coefficient, with p < 0.05 considered significant.Results: The in silico analysis demonstrated that epicatechin compounds have a strong binding affinity with the active site of caspase-3. Then the in vivo analysis indicated that administration of C. burmannii extract significantly reduced caspase-3 expression in the pancreas of the diabetic rats compared to the control group.Conclusion: C. burmannii extract has potential as an antiapoptotic agent through caspase-3 modulation. These findings provide scientific evidence supporting the promising role of C. burmannii as an adjunctive therapeutic agent in diabetes management.]]>
